COVID-19 Medicine Row: Now, Baba Backs Coronil Claim With ‘Scientific Proof’
New Delhi: Following the flak from researchers and doctors on his claims on a medicine to cure COVID-19, yoga guru Baba Ramdev on Friday released a research paper as proof of Coronil’s efficacy.
The study by Haridwar-based Patanjali Research Institute reported that Coronil is the “first evidence-based Ayurvedic medicine” against the coronavirus disease.
1st evidence-based medicine for Covid-19 (CoPP-WHO GMP certified)
With the guidance of Pujya Swami Ji & Pujya Acharya Ji & the hard work of scientists at Patanjali Research Institute, the efforts have been successful.#Patanjalis_EvidenceBased_Medicine4Corona #PatanjaliCoronil pic.twitter.com/L4xdZTajWW
— Patanjali Ayurved (@PypAyurved) February 19, 2021
Notably, the Ramdev-owned Patanjali had brought out its medicine against COVID-19 last year.
Releasing the research paper, Ramdev claimed that it was certified by the World Health Organization (WHO). “This research paper is to satisfy those who had earlier questioned the scientific relevance of the medicine,” he added.
Union Health Minister Harsh Vardhan and Union Transport Minister Nitin Gadkari were also present at the event, Hindustan Times reported.
The yoga guru further said the aim of the institute is to accredit the ancient medical science of India globally by providing scientific evidence and fulfil the Aatmanirbhar Bharat vision in healthcare.
On his part, the health minister echoed the need of using modern scientific tools to highlight the importance of Ayurveda at the international level. “Patanjali under the leadership of Acharyaji and Swamiji will help Ayurveda get the recognition it deserves at the international level,” Vardhan added.
Patanjali’s Coronil was under scrutiny earlier due to the lack of scientific evidence and trials that could determine its efficacy in combating the deadly virus.
Coronil was first advertised as a cure for the coronavirus infection but later licensed as an “immunity booster” amid the controversy over its trial data and composition.